Adicet Bio, Inc. — Director's Dealing 2021

Jun 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adicet Bio, Inc. (ACET)
CIK: 0001720580
Period of Report: 2021-06-04

Reporting Person: Galimi Francesco (SVP & Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-04	Common Stock	M	6983	$5.97	Acquired	6983	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-04	Employee Stock Option (Right to Buy)	$5.97	M	6983	Disposed	2029-10-15	Common Stock (6983)	Direct

Footnotes

F1: 25% of the option vested on September 23, 2020, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Dr. Galimi remains in continuous service as of the applicable vesting date.

F2: Received in exchange for an employee stock option to acquire 1,035,685 shares of common stock of Adicet Bio, Inc., a Delaware corporation ("Old Adicet"), for $0.740 per share in connection with the merger (the "Merger") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation ("resTORbio"). On the effective date of the Merger, resTORbio changed its name to "Adicet Bio, Inc."